Cargando…
Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease
Sickle cell disease (SCD) is caused by a single-point mutation, and the ensuing deoxygenation-induced polymerization of sickle hemoglobin (HbS), and reduction in bioavailability of vascular nitric oxide (NO), contribute to the pathogenesis of the disease. In a proof-of-concept study, we successfully...
Autores principales: | Huang, Boshi, Ghatge, Mohini S., Donkor, Akua K., Musayev, Faik N., Deshpande, Tanvi M., Al-Awadh, Mohammed, Alhashimi, Rana T., Zhu, Hongmei, Omar, Abdelsattar M., Telen, Marilyn J., Zhang, Yan, McMahon, Tim J., Abdulmalik, Osheiza, Safo, Martin K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610770/ https://www.ncbi.nlm.nih.gov/pubmed/36296435 http://dx.doi.org/10.3390/molecules27206835 |
Ejemplares similares
-
Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease
por: Alhashimi, Rana T., et al.
Publicado: (2022) -
Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde
por: Alhashimi, Rana T., et al.
Publicado: (2023) -
VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions
por: Abdulmalik, Osheiza, et al.
Publicado: (2020) -
An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling
por: Omar, Abdelsattar M., et al.
Publicado: (2020) -
Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease
por: Ahmed, Tarek A., et al.
Publicado: (2021)